ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0707

Single-Center Experience of AKI in COVID-19-Infected Patients in West Kent Hospital, United Kingdom

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • James, Matthew, Darent Valley Hospital, Dartford, Kent, United Kingdom
  • Hogsand, Tord Hurtig, Darent Valley Hospital, Dartford, Kent, United Kingdom
  • Jankowski, Kieran, Darent Valley Hospital, Dartford, Kent, United Kingdom
  • Rathod, Jeetendra Ramesh, Darent Valley Hospital, Dartford, Kent, United Kingdom
  • Chitalia, Nihil, Darent Valley Hospital, Dartford, Kent, United Kingdom
  • Kwan, Jonathan, Darent Valley Hospital, Dartford, Kent, United Kingdom
Background

The outcome of renal function and in COVID-19 positive patients is unclear. We studied the epidemiology of acute kidney injury (AKI) in the COVID-19 positive patients

Methods

Between 9th March 2020 and 26th April 2020 data was prospectively collected on 253 adult COVID-19 positive inpatients about co-morbidity, s. creatinine, demographics and AKI from digital records at our secondary care hospital. AKI stages were defined as per KDIGO Criteria

Results

Of the 253 patients, 58.9% were male with (mean + stdev) age 71.9 + 16.4 years. Common co-morbidities were Hypertension (54.1%), Cardiovascular Disease (34%), Diabetes Mellitus (28.3%), Chronic lung disease (23.3%), Dementia (20.5%), CKD (stage 3 - 5) 19.8% & 2 (0.8%) renal transplant. 2.8% (7) Patients on regular dialysis were excluded.
42.6% (105) patients had AKI. Of these 53.3% (56) had AKI 1, 20.9% (22) AKI 2 and 25.7% (25) had AKI 3. 2.4% (6) patient’s needed acute haemofiltrated. The mean systolic BP at admission in non-AKI patients was 136 + 22 mmHg (109 of 147 available) whilst in those with AKI it was 124 + 25 mmHg (78 of 105 available). The s,creatinine (median and range) in AKI patient at admission, peak and discharge or death was 126 (Range 30 - 1339), 173 (57 - 1339) and 113 (28 - 761) umol/L respectively. 52.4% (55) patients had recovered from AKI.
The overall mortality rate in COVID-19 infected patient was 36.4% with mean age of 77.5 + 12.4 years. Mortality in patients without AKI was 22% (31) & with AKI was 56.2% (59) with mean age of 77.7 + 11.7 Years. The stage wise AKI mortality was AKI1 25.7% (27), AKI2 10.4% (11) and AKI3 20% (21). 66.6% haemofiltration patients. 23% (25) AKI patients died with normal creatinine. Mortality in CKD patients as co-morbidity was 64%. All renal transplant patients survived without having AKI.
7.7% {19} patients required continuous positive airway pressure, 42.1% (8) patients developed AKI of these 75% (6) patients with CPAP died. A further 24 (9.75%) required mechanical ventilation with 62.5% (15) of these developed AKI with mortality of 80% (12).

Conclusion

Elderly patients were most commonly infected with COVID-19 infection. AKI was seen in 42.6% patients with COVID-19 infection. More than 60% COVID-19 infected patients died if they had AKI and were on any form of mechanical ventilatory support or had CKD as co-morbidity.